PHAM QUANG X (CEO and Chairman) sold 3.1% of their position (4.13K shares) of CADRENAL THERAPEUTICS, INC. on the open market
Open‑market sale worth $13.1K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 6/18/2026ACC: 0001213900-26-070248
DirectorOfficer10% Owner· CEO and Chairman
Since Jan 2023
-4.13K
Net shares
Net seller
$13.1K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
4.13K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−3.61K
Price / share
$3.18
Trade value
$11.49K
% of position
2.7%
6/16/2026
132.72K→129.10K
Common Stock
Direct
Shares
−513.00
Price / share
$3.16
Trade value
$1.62K
% of position
0.4%
6/17/2026
129.10K→128.59K
Total
Net shares
−4.13K
Net value
-$13.11K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/16/2026 | S · Sale | −3.61K | $3.18 | $11.49K | 2.7% | 132.72K | 129.10K |
| Common Stock Direct | 6/17/2026 | S · Sale | −513.00 | $3.16 | $1.62K | 0.4% | 129.10K | 128.59K |
| Total | −4.13K | -$13.11K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned200K
Total
200K indirect200K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 200K | Indirect |
| Total | 200K | 200K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported